Definitive Contract HHS261015123
Award Date
8/3/05
Potential Completion Date
9/29/05
Potential Value
$383K
Funding Federal Agency
Not listed
Contracting Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
622110 - General Medical and Surgical Hospitals
PSC Category
AN16 - R&D- Medical: Biomedical (Management/Support)
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35233, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer". The potential value of the contract is $492,314.00. The work is being performed under the National Cancer Institute's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" major...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB) for the "Evaluation of the Cancer Prevention Efficacy of GLG-302." The $574,237 contract is part of the NCI's Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The contract does not have a set-aside designation. UAB, a public research...
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Alabama at Birmingham (UAB) for the evaluation of "clinical-ready" agents (bazedoxifene and lapatinib) in combination for the prevention of estrogen receptor-positive and estrogen receptor-negative mammary cancers. The contract, which is part of the Preclinical Prevent Cancer Program, has a potential value of...
This is a firm fixed-price delivery order contract issued by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Prevention of Urinary Bladder Cancer with Two 'Clinically-Ready Agents (Everolimus and Naproxen) When Administered in Combination." The contract has a potential value of $432,272.00 and a completion date of April 30, 2020. It was awarded on July 9, 2018 and is part of the National Cancer Institute's...
This is a definitive contract awarded by the U.S. government to the University of Alabama at Birmingham (UAB), a non-profit educational institution, on December 15, 2002. The contract has a firm fixed price of $1,497,441.00 and a completion date of June 30, 2007. There is no set-aside designation for this contract. UAB has an extensive track record of delivering biomedical and public health research under federal grant awards from agencies like the National Institutes of Health (NIH), Centers...
This is a definitive federal contract awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency, to the University of Alabama at Birmingham (UAB), a non-profit educational institution. The contract, valued at $1,687,776.46, is for other ADP and telecommunications services. The contract does not have a set-aside designation. UAB has a strong track record of securing federal contracts and grants, including work for the Department of Defense, NASA, and the...
This federal contract was awarded by the National Cancer Institute, part of the Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) to evaluate whether a concurrent retinoid X receptor agonist can enhance the efficacy of the HER2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer. The contract, valued at $930,464.00, is a delivery order under the PREVENT Cancer Program, a preclinical...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to the University of Alabama at Birmingham (UAB) on September 17, 2018. The order, valued at $1,271,040.50, is for the preclinical development of the chemopreventive agent 4-methylumbelliferone (4-MU) under the agency's Preclinical Prevent Cancer Program. The work is being performed in Birmingham, Alabama and has a completion date of April 14,...
This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Preclinical Drug Development Program (PREVENT). The $1,498,585.64 task order is for the research and development of a novel EPA analogue TP-252 and naproxen for colorectal cancer prevention in familial adenomatous polyposis (FAP) and Lynch syndrome models. The contract has no set-aside designation. UAB has performed numerous federal...
This is a Firm Fixed Price delivery order awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Cancer Program (PREVENT) indefinite delivery contract. The contract has a ceiling value of $922,642.00 and no set-aside designation. The contract describes a research and development project in the area of biomedical basic research for the Preclinical Prevention Cancer Program. The work involves conducting preliminary...